Symbiotix Biotherapies' Unattributed VC Round

Symbiotix Biotherapies raised a round of funding on November 07, 2017. Investors include Kairos Ventures.

Symbiotix Biotherapies develops molecular therapeutics based on the human microbiome. It manufactures Reglemers, a zwitterionic polysaccharide which results in increased production of anti-inflammator…

Articles about Symbiotix Biotherapies' Unattributed VC Round: